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ABSTRACT
Acute graft-versus-host disease (aGVHD) remains one of the most severe complications after allogeneic
transplantation; in particular, the presence of gut involvement has been related to increased mortality and
poorer response. The use of systemic steroids remains the standard for first-line treatment despite its severe
secondary effects. Beclomethasone dipropionate (BDP) is a topically active corticosteroid with low absorption,
thereby avoiding many of the deleterious side effects associated with systemic steroids. In the present study we
analyzed the efficacy of BDP in a series of 26 patients who were diagnosed with grade 1 and 2 gastrointestinal
aGVHD. Twenty patients (77%) responded to BDP treatment, 17 (65.5%) reached complete remission (CR),
and 3 (11.5%) showed partial response. Among those patients who reached CR, 5 relapsed, although 1 of them
reached second CR after a second course of BDP; therefore, 13 (50%) of the 26 patients did not require
systemic steroids to treat gastrointestinal aGVHD. CR rates in those showing gastrointestinal symptoms were
68% for patients with persistent nausea, 50% for those with vomiting, and 54% for those with diarrhea
(P  .2). No patient included in the study developed any symptom related to adrenal axis suppression.
Thirteen patients (50%) developed >1 infectious episode during the first 100 days after transplantation.
Transplant-related mortality was 0% at 100 days, and overall transplant-related mortality was 30%, with only
2 patients dying due to infectious complications. Therefore, our study shows that monotherapy with oral BDP
is an effective initial therapeutic approach for mild to moderate intestinal GVHD, which avoids complications
related to systemic steroids.
© 2006 American Society for Blood and Marrow Transplantation
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eNTRODUCTION
Acute graft-versus-host disease (aGVHD) remains
ne of the most severe complications after allogeneic
ransplantation and its frequency ranges from 30% to
0% among recipients of HLA-matched sibling or
nrelated donor transplants, respectively. The patho-
hysiology of aGVHD is complex and can be summa-
ized in a 3-step process [1]. In step 1, the condition-
ng regimen leads to damage of host tissues, which
nduces secretion of inﬂammatory cytokines. Donor
-cell activation in step 2 is characterized by donor
-cell interaction with host antigen-presenting cells a
36nd subsequent proliferation, differentiation, and se-
retion of cytokines. These cytokines in turn stimulate
roduction of inﬂammatory chemokines, thus recruit-
ng effector cells into target organs. In step 3, effector
unctions of mononuclear phagocytes are triggered by
secondary signal provided by lipopolysaccharide that
eaks through the intestinal mucosa that was damaged
uring step 1 [1]. Following this pattern, the gut is
onsidered to play a major role in the pathologic
rocess leading to aGVHD [2-4], and, although the
xact pathogenic mechanisms have yet to be fully
stablished, the gut plays a critical role in initiating
nd propagating an inﬂammatory process in which it
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Oral BDP Treatment of GI-aGVHD 937erves as a primary target [3,4]. In addition, gastroin-
estinal (GI) GVHD is particularly important because
f its frequency, severity, and effect on the general
ondition of the patient [2-6]. Accordingly, the pres-
nce of gut involvement among patients who have
een diagnosed with GVHD has been related to an
ncreased mortality and a poorer response [7,8].
Treatment of GI-GVHD relies on systemic immu-
osuppressive therapy such as glucocorticoids. The risk
f systemic immunosuppression includes local and dis-
eminated infections, Epstein-Barr virus-associated lym-
hoproliferative disease, hypothalamic-pituitary-adrenal
xis suppression, myopathy, glucose intolerance, neuro-
sychiatric disease, and bone demineralization [9,10].
ystemic administration of glucocorticoids also causes
uid and electrolyte disturbances, hyperglycemia, and
ypertension, among other complications. Unfortu-
ately, aside from these secondary effects, the success
ate is only approximately 50% if we consider patients
ho do not respond and those who relapse after initial
esponse [9].
Beclomethasone dipropionate (BDP) is a topically
ctive corticosteroid with low absorption, thus avoid-
ng many of the deleterious side effects associated with
ystemic corticosteroids, such as adrenal suppression.
revious experience using BDP or other topically ac-
ive glucocorticoids for the treatment of rhinitis,
sthma, and inﬂammatory bowel disease, in the form
f enema [11,12], showed the anti-inﬂammatory prop-
rties of BDP, which were reported to be 500-5000
imes more potent than dexamethasone and hydrocor-
isone as topical anti-inﬂammatory agents [13,14]. In
he ﬁeld of allogeneic stem cell transplantation, pre-
ious studies have suggested its efﬁcacy in the treat-
ent of less severe forms of GI-GHVD, but in asso-
iation with systemic steroids [7,8,15].
In the present report we describe the safety and
fﬁcacy of BDP as a single agent in a series of patients
iagnosed with gut aGVHD.
ETHODS
atient Characteristics
BDP was administered in 26 patients who were
ndergoing allogeneic peripheral blood stem cell
ransplantation and had biopsy-proven gut GVHD
nd clinical symptoms of aGVHD that developed or
ersisted14 days after transplantation. Patients were
ble to swallow medication and had conﬁrmed nega-
ive stool cultures. All patients signed informed con-
ent. Cessation rules included transplant-related mor-
ality (TRM) and response evaluation for the ﬁrst 6
atients and then both parameters were analyzed for
very 10 patients.
GVHD ﬂared at a median of 42 days (range, 17-90
ays) after transplantation. Eighteen patients had GI- §GVHD and 8 had GI and skin involvement; 2 pa-
ients had abnormal liver function tests without con-
rmatory liver biopsy. Symptoms of GI involvement
onsisted of nausea (n  19), vomiting (n  12),
nd/or diarrhea (n  13). Seven patients had grade 1
I-GVHD (stage B overall aGVHD) and 19 had
rade 2 GI-GVHD (stage C aGVHD). No patient
eceived systemic corticoids before BDP. All patients
iagnosed with cutaneous GVHD had a skin rash with
50% body surface area involved.
Twenty-three percent of patients underwent trans-
lantation in ﬁrst complete remission (CR), whereas
1% had untreated or relapse/progressive disease at
ransplantation. Sixteen patients had received reduced
ntensity conditioning regimens based on ﬂudarabine
lus melphalan or busulphan, 5 received cyclophospha-
ide plus total body irradiation, and 5 busulphan plus
yclophosphamide. All had received cyclosporine and
ethotrexate as GVHD prophylaxis. Cyclosporine was
aintained at therapeutic levels while on BDP.
Other patient characteristics are summarized in
able 1.
DP Treatment and Response Assessment
BDP was prepared as an emulsion of 250 mg of
DP in 500 mL of olive oil. BDP was given orally 4
imes a day at a dose of 2 mg, for a total dose of 8
able 1. Patient Characteristics
Patients, n (%)
ge* 46 (14-69)
ale/female 50/50
iagnosis
Acute leukemia 10 (39.4%)
Myelodysplastic syndrome 3 (11.5%)
Chronic lymphoproliferative disorders 9 (34.6%)
Chronic myeloproliferative disorders 3 (11.5%)
Hodgkin disease 1 (3.8%)
isease status at transplantation
First CR 6 (23%)
At least second CR 3 (11%)
PR 8 (31%)
Relapse/progression 6 (23%)
Untreated 2 (8%)
Others† 1 (4%)
onditioning
Myeloablative 10 (38.5%)
Reduced intensity 16 (61.5%)
rade of GI-GVHD
1 7 (27%)
2 19 (73%)
rgan involvement
GI tract‡ 18 (69%)
Skin and GI§ 8 (31%)
Continuous variables presented as median (range).
One patient with acute myelodysplastic leukemia underwent trans-
plantation under aplasia after the ﬁnal course of chemotherapy.
One patient had abnormal liver function tests.
One patient had abnormal liver function tests.
m
w
p
a
s
r
s
r
v
p
s
t
c
g
c
2
s
a
r
t
s
S
t
t
u
t
r
d
n
G
t
t
t
c
u
c
d
a
c
w
p
c
t
R
C
r
p
S
a
n
t
(
C
2
t
6
o
t
w
c
v
h
r
A
a
a
p
r
(
t
b
n
i
i
a
r
t
v
v
P
r
1
m
t
s
T
s
w
t
c
e
T
(
C. Castilla et al.938g/day over a mean of 28 days (range, 4-60 days) and
as started on day 47 (range, 17-84 days) after trans-
lantation.
Response was deﬁned as follows: CR was deﬁned
s resolution of GI symptoms with no need of adding
ystemic steroids to control GVHD symptoms. Partial
esponse (PR) was deﬁned as an improvement in GI
core from baseline, with improvement consisting of
esolution of diarrhea or a decrease 500 mL in stool
olume for 3 days with improvement of abdominal
ain or bleeding. Patients were classiﬁed as nonre-
ponders in the event of no improvement in GI symp-
oms and those who had worsening GI scores were
lassiﬁed as having progressive disease. These latter 2
roups and those who relapsed after CR or PR re-
eived systemic steroids.
Response was evaluated on days 3, 7, 14, 21, and
8 after the beginning of treatment, and steroids were
tarted in the event of progression at day 3, absence of
ny improvement at day 7, or absence of complete
esponse at day 14.
Patients who had responded (CR or PR) and after
apering BDP treatment again presented with GI
ymptoms received a second BDP course.
tatistical Analysis
Events analyzed were calculated from the time of
ransplantation using Kaplan-Meier product-limit es-
imates. TRM was deﬁned as death due to causes
nrelated to the underlying disease and relapsing pa-
ients were censored at the time of relapse. GVHD-
elated mortality was deﬁned as death due to causes
irectly related to GVHD; deaths attributed to immu-
osuppression in patients requiring treatment for
VHD were also considered as GVHD-related mor-
ality. Overall survival was calculated from transplan-
ation until death from any cause, and surviving pa-
ients were censored at ﬁnal follow-up.
Patients who had evidence of engraftment were
ategorized as having aGVHD, whereas patients who
nderwent engraftment and survived 100 days were
ategorized as having chronic GVHD (cGVHD). The
ay of aGVHD was calculated from transplantation to
diagnosis of aGVHD and the same applied for
GVHD. Cumulative incidence estimates for GVHD
as performed by taking into account death as a com-
eting risk.
For statistical analyses, SPSS 10.0 (SPSS Inc, Chi-
ago, Ill, USA) was used. Differences were considered
o be statistically signiﬁcant at P  .05.
ESULTS
linical Efficacy
Among 26 patients included in the study, 20 (77%)
esponded to BDP treatment as measured by im- wrovement or complete resolution of GI symptoms.
eventeen (65.5%) reached CR and 3 (11.5%)
chieved partial response. Four patients (15.4%) did
ot respond and 2 patients (7.6%) progressed. Among
hose patients who reached complete response, 5
29%) relapsed, although 1 of them reached second
R after a second course of BDP, so that 13 (50%) of
6 patients did not require systemic corticosteroids to
reat GI-aGVHD. Responses occurred at a median of
days (range, 3-14 days) after treatment was started.
No signiﬁcant differences were observed in terms
f response rate depending on the different GI symp-
oms. Accordingly, 68% of patients (13 of 19 cases)
ho complained of persistent nausea reached CR
ompared with 50% (6 of 12) among those who had
omiting and 54% (7 of 13 patients) among those who
ad diarrhea (P .2), although a trend toward a lower
esponse rate was observed within the latter group.
ccordingly, 16% of patients who complained of di-
rrhea progressed during therapy compared with 0%
mong those without it (P  .24).
Regarding the grade of acute GVHD, 86% of
atients classiﬁed as having grade 1 GI-GVHD
eached CR compared with 59% of those with grade 2
P  .19).
Some patients had GVHD involvement outside
he GI tract and received topical corticosteroids (clo-
etasol) in addition to BDP without systemic immu-
osuppression due to a high risk of relapse. Interest-
ngly, 6 (75%) of the 8 patients who had skin and gut
nvolvement reached CR, including 1 patient who had
bnormal liver function tests.
No signiﬁcant differences in terms of response
ate to BDP were observed between different intensi-
ies of the conditioning regimen. Accordingly, 70%
ersus 81% of patients who received myeloablative
ersus reduced intensity conditioning reached CR or
R, respectively (P  .42).
Patients who did not respond to BDP or who
elapsed after CR received corticosteroids at a dose of
mg/kg per day except for 1 patient who received 2
g/kg per day. Response rate was 69% after systemic
reatment in this subset of patients. These results are
ummarized in Table 2.
oxicity and Outcome
No patient included in the study developed any
ymptoms related to adrenal axis suppression, which
ould reﬂect systemic absorption of BDP. Further,
hey did not develop Cushing syndrome or hypergly-
emia during treatment with BDP.
Thirteen patients (50%) developed 1 infectious
pisode during the ﬁrst 100 days after transplantation.
RM was 0% at 100 days, and overall TRM was 30%
Figure 1), ranging from 20% to 67% among patients
ho did or did not respond to BDP (P  .02). Only 2
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Oral BDP Treatment of GI-aGVHD 939atients died due to infectious complications and 2
dditional patients died due to GVHD; 1 patient de-
eloped veno-occlusive disease, and the remaining 9
atients died due to progressive disease.
After a median follow-up of 927 days (range, 627-
225 days), 15 patients (58%) developed cGVHD.
rojected overall survival at 4 years was 42% (Figure
), ranging from 50% to 16% among patients who
id or did not respond to oral BDP, respectively
P  .03).
ISCUSSION
Systemic steroids are considered the gold standard
s ﬁrst-line treatment for aGVHD and cGVHD
16,17]. Unfortunately, 50% of patients with grade
-4 aGVHD achieve durable responses after initial
able 2. Response to Treatment With BDP
CR
verall 17 (65.4%) 3
rade of GI-GVHD
1 (stage B aGVHD) 6 (85.7%)
2 (stage C aGVHD) 11 (58%) 3
rgan involvement
GI tract 11 (61%) 3
Skin and GI 6† (75%)
ympthoms
Diarrhea: yes/no‡ 54%/77%
Vomiting: yes/no§ 50%/78%
R indicates.
One patient had abnormal liver function tests.
One patient had abnormal liver function tests.
P  .32.
P  .24.Figure 1. Transplant-related mortality.herapy [9,17-19]. Accordingly, new strategies have
een reported in an attempt to improve these results,
ncluding the addition of other immunosuppressive
rugs such as Daclizumab, which has shown no ben-
ﬁt in terms of response [20]. The use of higher doses
f steroids does not improve response rate but even
ncreases treatment-related morbidity [21]. In addi-
ion, gut GVHD is frequently the most severe and the
ost difﬁcult to treat and has been related to in-
reased mortality and poorer outcome [2,6-8], al-
hough upper GI-aGVHD has been described as a
istinct entity that presents with nausea and vomiting
NR Progressive Disease
) 4 (15.4%) 2 (7.7%)
1 (14.3%)
3 (15.8%) 2 (10.2%)
3* (17%) 1 (5%)
1 (12.5%) 1 (12.5%)
15%/15% 16%/0%
25%/7% 8%/8%PR
(11.5%
(16%)
(17%)
15%/8%
17%/7%Figure 2. Overall survival.
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C. Castilla et al.940nd seems to be more responsive to immunosuppres-
ive treatment [22,23].
In addition to a success rate 50% [9,17], the use
f systemic steroids is associated with the development
f severe complications such as opportunistic infec-
ions, which lead to an increase in the morbidity and
ortality of the procedure [24]. Moreover, as with any
mmunosuppressive drug, steroids may also hamper
he antileukemic effect of the graft [25,26]. Accord-
ngly, whenever possible, aGVHD should be managed
y using therapeutic approaches with a speciﬁc effect
n the organ involved to prevent severe immunosup-
ression. Among these strategies, topical treatment is
useful approach in early-stage aGVHD that is lim-
ted to the skin; however, as far as liver and gut
nvolvement is concerned, this strategy is obviously
ore complicated to perform. In accordance with this
trategy, Takatsuka et al [5] reported promising pre-
iminary results by using sulfasalazine or betametha-
one enemas.
BDP has been used for the treatment of asthma
nd inﬂammatory bowel disease. Although systemic
bsorption of BDP may occur, adrenal suppression is
ot a prerequisite for clinical efﬁcacy because the
iological effect is primarily topical, and BDP is rap-
dly metabolized by intestinal cells and has a high
fﬁnity to local steroids receptors [27,28]. In a pro-
pective, randomized trial that included 60 patients,
cDonald at al [15] showed that the addition of BDP
o systemic steroids increases the response rate com-
ared with placebo plus prednisone (“durable re-
ponse” at 30 days, 71% versus 41%, respectively; P
02). These investigators also conﬁrmed that BDP
ay suppress adrenal axis, but suppression is not a
rerequisite for clinical response to BDP [29]. After
his experience, only 1 study has reported on the use of
PD as a single agent for the treatment of GVHD. In
series of 15 patients with aGVHD or cGVHD, Iyer
t al [30] reported a response rate of 60%, although
nly 2 patients were diagnosed with aGVHD and
either of these 2 patients responded to treatment. In
he present study, response rate reached 77%, thus
4% of patients did not require systemic immunosup-
ression. In addition, we observed no secondary ef-
ects related to hypothalamic-pituitary-adrenal axis
uppression or systemic immunosuppression. Because
he response rate using systemic steroids have been
eported in the range of 50% [7-9,17-19], these results
sing BDP as a single agent are very promising in
erms of efﬁcacy and safety. Moreover, the use of BDP
id not preclude the subsequent use of systemic ste-
oids because the response rate to 6-methylpred-
isolone among patients who did not respond or
aintained CR after BDP reached 69%.
It is important to note that the present study
ncluded patients who complained of symptoms of
pper and lower GI involvement such as diarrhea and,nterestingly, the response rate was similar in both
ubsets of patients, although, in this regard, it must
lso be speciﬁed that only patients diagnosed with
rade 2 GI-GVHD were included in this study, so
he results may not apply to patients with more severe
iarrhea.
Therefore, our study has shown that monotherapy
ith oral BDP is an effective initial therapeutic ap-
roach for mild to moderate intestinal GVHD, thus
voiding complications related to systemic steroids.
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